Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Eli Lilly and Company (LLY) Insider Trading Activity

    Healthcare • Drug Manufacturers - General • 43,000 employees

    Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

    Total Value

    -$2,298,834,751.53

    Total Shares

    -709,889

    Average Trade Value

    -$13,288,062.15

    Most Active Insider

    Lilly Endowment Inc

    Total Activity: $2,383,533,766

    Largest Single Transaction

    $1,599,999,998

    by Lilly Endowment Inc on Feb 24, 2025

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Mar 3, 2025 17,393 $16,207,093 96,032,486 (-0.0%) Sale
    Mar 3, 2025 25,057 $23,321,552 96,049,879 (-0.0%) Sale
    Mar 3, 2025 68,251 $63,454,661 96,074,936 (-0.1%) Sale
    Mar 3, 2025 25,984 $24,138,720 96,143,187 (-0.0%) Sale
    Mar 3, 2025 3,997 $3,732,139 96,017,790 (-0.0%) Sale
    Mar 3, 2025 812 $759,130 96,016,978 (-0.0%) Sale
    Mar 3, 2025 10,699 $9,979,706 96,021,787 (-0.0%) Sale
    Mar 3, 2025 3,691 $3,416,220 96,198,597 (-0.0%) Sale
    Mar 3, 2025 7,665 $7,086,515 96,202,288 (-0.0%) Sale
    Mar 3, 2025 8,197 $7,567,905 96,209,953 (-0.0%) Sale
    Mar 3, 2025 21,025 $19,507,205 96,169,171 (-0.0%) Sale
    Mar 3, 2025 18,828 $17,367,343 96,218,150 (-0.0%) Sale
    Mar 3, 2025 8,401 $7,787,962 96,190,196 (-0.0%) Sale
    EVP Pres., Mfg. Operations
    Officer
    Mar 1, 2025 1,260 $1,159,994 39,748 (-3.2%) Payment of Exercise Price
    EVP Pres., Mfg. Operations
    Officer
    Mar 1, 2025 2,837 $10,000 41,008 (+6.9%) Exercise/Conversion
    Evp, Chief People Officer
    Officer
    Mar 1, 2025 2,403 $10,000 10,905 (+22.0%) Exercise/Conversion
    Evp, Chief People Officer
    Officer
    Mar 1, 2025 1,066 $981,392 9,838 (-10.8%) Payment of Exercise Price
    Feb 25, 2025 50,118 $45,184,685 96,376,282 (-0.1%) Sale
    Feb 25, 2025 36,219 $32,723,287 96,292,158 (-0.0%) Sale
    Feb 25, 2025 3,290 $2,991,870 96,240,854 (-0.0%) Sale
    Feb 25, 2025 5,191 $4,714,944 96,244,144 (-0.0%) Sale
    Feb 25, 2025 3,606 $3,283,382 96,237,248 (-0.0%) Sale
    Feb 25, 2025 4,962 $4,501,953 96,249,335 (-0.0%) Sale
    Feb 25, 2025 8,559 $7,758,391 96,254,297 (-0.0%) Sale
    Feb 25, 2025 270 $246,118 96,236,978 (-0.0%) Sale
    Feb 25, 2025 18,159 $16,425,542 96,273,999 (-0.0%) Sale
    Feb 25, 2025 11,143 $10,089,006 96,262,856 (-0.0%) Sale
    Feb 25, 2025 47,905 $43,233,592 96,328,377 (-0.0%) Sale
    Feb 25, 2025 35,578 $32,038,025 96,426,400 (-0.0%) Sale
    Feb 24, 2025 6,444 $5,653,392 96,515,966 (-0.0%) Sale
    Feb 24, 2025 1,631 $1,434,419 96,512,517 (-0.0%) Sale
    Feb 24, 2025 1,818 $1,599,999,998 96,514,148 (-0.0%) Sale
    Feb 24, 2025 578 $515,503 96,461,978 (-0.0%) Sale
    Feb 24, 2025 2,569 $2,288,578 96,462,556 (-0.0%) Sale
    Feb 24, 2025 3,835 $3,413,131 96,465,125 (-0.0%) Sale
    Feb 24, 2025 4,230 $3,760,373 96,468,960 (-0.0%) Sale
    Feb 24, 2025 5,169 $4,589,421 96,473,190 (-0.0%) Sale
    Feb 24, 2025 5,754 $5,102,987 96,478,359 (-0.0%) Sale
    Feb 24, 2025 2,628 $2,328,269 96,484,113 (-0.0%) Sale
    Feb 24, 2025 1,700 $1,503,891 96,486,741 (-0.0%) Sale
    Feb 24, 2025 1,788 $1,580,193 96,488,441 (-0.0%) Sale
    Feb 24, 2025 6,361 $5,614,168 96,490,229 (-0.0%) Sale
    Feb 24, 2025 14,595 $12,865,741 96,496,590 (-0.0%) Sale
    Feb 24, 2025 1,332 $1,172,957 96,511,185 (-0.0%) Sale
    Feb 21, 2025 1,221 $1,081,160 96,549,253 (-0.0%) Sale
    Feb 21, 2025 19,490 $17,145,548 96,572,064 (-0.0%) Sale
    Feb 21, 2025 9,766 $8,578,728 96,591,554 (-0.0%) Sale
    Feb 21, 2025 6,152 $5,486,304 96,527,333 (-0.0%) Sale
    Feb 21, 2025 2,700 $2,396,120 96,544,724 (-0.0%) Sale
    Feb 21, 2025 5,182 $4,583,194 96,550,474 (-0.0%) Sale
    Feb 21, 2025 4,079 $3,599,718 96,559,296 (-0.0%) Sale
    Feb 21, 2025 20,542 $18,021,764 96,601,320 (-0.0%) Sale
    Feb 21, 2025 5,781 $5,089,292 96,566,283 (-0.0%) Sale
    Feb 21, 2025 3,640 $3,215,671 96,555,656 (-0.0%) Sale
    Feb 21, 2025 2,700 $2,402,973 96,540,937 (-0.0%) Sale
    Feb 21, 2025 1,087 $966,066 96,543,637 (-0.0%) Sale
    Feb 21, 2025 7,452 $6,638,406 96,533,485 (-0.0%) Sale
    Feb 21, 2025 3,357 $2,997,059 96,523,976 (-0.0%) Sale
    Feb 21, 2025 1,829 $1,621,297 96,547,424 (-0.0%) Sale
    Feb 21, 2025 2,908 $2,563,594 96,563,375 (-0.0%) Sale
    Feb 21, 2025 1,566 $1,399,613 96,522,410 (-0.0%) Sale
    Feb 20, 2025 8,937 $7,841,646 96,627,610 (-0.0%) Sale
    Feb 20, 2025 200 $176,029 96,621,862 (-0.0%) Sale
    Feb 20, 2025 3,127 $2,746,450 96,624,483 (-0.0%) Sale
    Feb 20, 2025 2,421 $2,129,228 96,622,062 (-0.0%) Sale
    Feb 19, 2025 1,293 $1,138,413 96,636,547 (-0.0%) Sale
    Feb 19, 2025 1,467 $1,288,771 96,640,229 (-0.0%) Sale
    Feb 19, 2025 2,389 $2,101,126 96,637,840 (-0.0%) Sale
    Feb 19, 2025 4,836 $4,242,976 96,641,696 (-0.0%) Sale
    Director
    Feb 18, 2025 11 $9,429 72,683 (+0.0%) Grant
    Director
    Feb 18, 2025 17 $14,572 16,228 (+0.1%) Grant
    Director
    Feb 18, 2025 13 $11,144 54,719 (+0.0%) Grant
    Director
    Feb 18, 2025 11 $9,429 1,903 (+0.6%) Grant
    Director
    Feb 18, 2025 5 $4,286 2,545 (+0.2%) Grant
    Feb 13, 2025 6,470 $5,683,106 96,664,979 (-0.0%) Sale
    Feb 13, 2025 10,529 $9,238,892 96,671,449 (-0.0%) Sale
    Feb 13, 2025 3,175 $2,796,511 96,656,646 (-0.0%) Sale
    Feb 13, 2025 5,158 $4,536,796 96,659,821 (-0.0%) Sale
    Feb 13, 2025 6,789 $5,985,379 96,649,857 (-0.0%) Sale
    Feb 13, 2025 3,025 $2,669,677 96,646,832 (-0.0%) Sale
    Feb 13, 2025 300 $265,034 96,646,532 (-0.0%) Sale
    Evp, Cso Pres. Lrl Lly Imm
    Officer
    Feb 10, 2025 18,771 $16,309,746 136,660 (+13.7%) Grant
    EVP Pres., Mfg. Operations
    Officer
    Feb 10, 2025 5,974 $5,190,689 38,171 (+15.7%) Grant
    Evp, Gc Secretary
    Officer
    Feb 10, 2025 10,320 $8,966,842 28,837 (+35.8%) Grant
    President, Chair, and CEO
    Director, Officer
    Feb 10, 2025 55,131 $47,902,223 539,613 (+10.2%) Grant
    Evp, Cso Pres. Lrl Lly Imm
    Officer
    Feb 10, 2025 340 $293,750 118,598 (-0.3%) Sale
    Evp, Cso Pres. Lrl Lly Imm
    Officer
    Feb 10, 2025 710 $614,690 117,888 (-0.6%) Sale
    Evp, Cso Pres. Lrl Lly Imm
    Officer
    Feb 10, 2025 3,950 $3,407,626 118,938 (-3.3%) Sale
    EVP Pres, Lilly Neuroscience
    Officer
    Feb 10, 2025 6,828 $5,932,713 74,209 (+9.2%) Grant
    EVP Pres., Lilly Oncology
    Officer
    Feb 10, 2025 6,103 $5,302,775 19,561 (+31.2%) Grant
    EVP CFO
    Officer
    Feb 10, 2025 2,895 $2,515,408 13,969 (+20.7%) Grant
    Svp, Finance, Cao
    Officer
    Feb 10, 2025 1,359 $1,180,808 6,839 (+19.9%) Grant
    EVP President, Lly Int'l
    Officer
    Feb 10, 2025 7,123 $6,189,032 28,759 (+24.8%) Grant
    Evp, Hr Diversity
    Officer
    Feb 10, 2025 919 $798,501 8,962 (+10.3%) Grant
    Evppres, Cardmethlth, Lly Usa
    Officer
    Feb 10, 2025 7,170 $6,229,870 53,650 (+13.4%) Grant
    EVP Cido
    Officer
    Feb 10, 2025 6,815 $5,921,417 19,718 (+34.6%) Grant
    Feb 6, 2025 18,918 $16,483,689 96,803,393 (-0.0%) Sale
    Feb 6, 2025 15,637 $13,657,715 96,775,600 (-0.0%) Sale
    Feb 6, 2025 12,726 $11,204,670 96,701,727 (-0.0%) Sale
    Feb 6, 2025 12,156 $10,602,937 96,791,237 (-0.0%) Sale
    Feb 6, 2025 28,727 $25,003,579 96,822,311 (-0.0%) Sale
    Feb 6, 2025 2,239 $1,975,781 96,695,337 (-0.0%) Sale
    Feb 6, 2025 4,855 $4,289,592 96,690,482 (-0.0%) Sale
    Feb 6, 2025 5,736 $4,979,984 96,874,409 (-0.0%) Sale
    Feb 6, 2025 15,032 $13,143,199 96,760,568 (-0.0%) Sale
    Feb 6, 2025 9,301 $8,140,291 96,751,267 (-0.0%) Sale
    Feb 6, 2025 9,278 $8,141,213 96,733,089 (-0.0%) Sale
    Feb 6, 2025 6,228 $5,470,439 96,726,861 (-0.0%) Sale
    Feb 6, 2025 12,408 $10,913,382 96,714,453 (-0.0%) Sale
    Feb 6, 2025 2,700 $2,391,422 96,684,577 (-0.0%) Sale
    Feb 6, 2025 2,325 $2,061,491 96,682,252 (-0.0%) Sale
    Feb 6, 2025 274 $243,125 96,681,978 (-0.0%) Sale
    Feb 6, 2025 5,070 $4,390,960 96,886,908 (-0.0%) Sale
    Feb 6, 2025 6,763 $5,864,779 96,880,145 (-0.0%) Sale
    Feb 6, 2025 3,205 $2,835,024 96,687,277 (-0.0%) Sale
    Feb 6, 2025 4,151 $3,658,563 96,697,576 (-0.0%) Sale
    Feb 6, 2025 8,900 $7,800,770 96,742,367 (-0.0%) Sale
    Feb 6, 2025 23,371 $20,314,657 96,851,038 (-0.0%) Sale
    EVP President, Lly Int'l
    Officer
    Feb 1, 2025 3,269 $10,000 23,071 (+14.2%) Exercise/Conversion
    Evp, Cso Pres. Lrl Lly Imm
    Officer
    Feb 1, 2025 8,989 $10,000 126,892 (+7.1%) Exercise/Conversion
    Evp, Cso Pres. Lrl Lly Imm
    Officer
    Feb 1, 2025 4,003 $3,246,753 122,888 (-3.3%) Payment of Exercise Price
    EVP Pres., Lilly Oncology
    Officer
    Feb 1, 2025 1,409 $1,142,812 13,458 (-10.5%) Payment of Exercise Price
    EVP President, Lly Int'l
    Officer
    Feb 1, 2025 1,434 $1,163,089 21,636 (-6.6%) Payment of Exercise Price
    Evppres, Cardmethlth, Lly Usa
    Officer
    Feb 1, 2025 3,433 $10,000 48,016 (+7.1%) Exercise/Conversion
    President, Chair, and CEO
    Director, Officer
    Feb 1, 2025 11,903 $9,654,285 484,481 (-2.5%) Payment of Exercise Price
    President, Chair, and CEO
    Director, Officer
    Feb 1, 2025 26,561 $10,000 496,385 (+5.4%) Exercise/Conversion
    EVP Pres., Mfg. Operations
    Officer
    Feb 1, 2025 1,281 $1,038,993 32,197 (-4.0%) Payment of Exercise Price
    Evppres, Cardmethlth, Lly Usa
    Officer
    Feb 1, 2025 1,535 $1,245,008 46,480 (-3.3%) Payment of Exercise Price
    EVP Pres., Lilly Oncology
    Officer
    Feb 1, 2025 3,023 $10,000 14,868 (+20.3%) Exercise/Conversion
    EVP Pres, Lilly Neuroscience
    Officer
    Feb 1, 2025 3,269 $10,000 68,838 (+4.7%) Exercise/Conversion
    EVP Cido
    Officer
    Feb 1, 2025 1,466 $1,189,043 12,903 (-11.4%) Payment of Exercise Price
    EVP Cido
    Officer
    Feb 1, 2025 3,269 $10,000 14,370 (+22.7%) Exercise/Conversion
    EVP Pres, Lilly Neuroscience
    Officer
    Feb 1, 2025 1,457 $1,181,744 67,380 (-2.2%) Payment of Exercise Price
    Evp, Gc Secretary
    Officer
    Feb 1, 2025 2,166 $1,756,799 18,516 (-11.7%) Payment of Exercise Price
    Evp, Gc Secretary
    Officer
    Feb 1, 2025 4,904 $10,000 20,683 (+23.7%) Exercise/Conversion
    EVP Pres., Mfg. Operations
    Officer
    Feb 1, 2025 2,861 $10,000 33,479 (+8.5%) Exercise/Conversion
    Director
    Jan 21, 2025 6 $4,454 2,539 (+0.2%) Grant
    Director
    Jan 21, 2025 13 $9,651 72,671 (+0.0%) Grant
    Director
    Jan 21, 2025 13 $9,651 1,892 (+0.7%) Grant
    Director
    Jan 21, 2025 19 $14,105 16,211 (+0.1%) Grant
    Director
    Jan 21, 2025 15 $11,135 54,705 (+0.0%) Grant
    Director
    Dec 16, 2024 12 $9,348 2,532 (+0.5%) Grant
    Director
    Dec 16, 2024 19 $14,801 16,191 (+0.1%) Grant
    Director
    Dec 16, 2024 12 $9,348 3,032 (+0.4%) Grant
    Director
    Dec 16, 2024 12 $9,348 1,878 (+0.6%) Grant
    Director
    Dec 16, 2024 15 $11,685 54,689 (+0.0%) Grant
    Director
    Nov 18, 2024 302 $219,614 54,586 (+0.6%) Grant
    Director
    Nov 18, 2024 320 $232,704 72,540 (+0.4%) Grant
    Director
    Nov 18, 2024 13 $9,454 2,214 (+0.6%) Grant
    Director
    Nov 18, 2024 302 $219,614 16,146 (+1.9%) Grant
    Director
    Nov 18, 2024 20 $14,544 15,844 (+0.1%) Grant
    Director
    Nov 18, 2024 302 $219,614 6,248 (+4.8%) Grant
    Director
    Nov 18, 2024 13 $9,454 1,561 (+0.8%) Grant
    Director
    Nov 18, 2024 302 $219,614 3,015 (+10.0%) Grant
    Director
    Nov 18, 2024 302 $219,614 23,118 (+1.3%) Grant
    Director
    Nov 18, 2024 13 $9,454 2,712 (+0.5%) Grant
    Director
    Nov 18, 2024 302 $219,614 1,864 (+16.2%) Grant
    Director
    Nov 18, 2024 302 $219,614 9,153 (+3.3%) Grant
    Director
    Nov 18, 2024 16 $11,635 54,283 (+0.0%) Grant
    Director
    Nov 18, 2024 302 $219,614 21,464 (+1.4%) Grant
    Director
    Nov 18, 2024 302 $219,614 2,516 (+12.0%) Grant
    Svp, Finance, Cao
    Officer
    Nov 8, 2024 900 $723,042 5,480 (-16.4%) Sale
    Evp, Hr Diversity
    Officer
    Nov 1, 2024 1,534 $10,000 8,724 (+17.6%) Exercise/Conversion
    EVP CFO
    Officer
    Nov 1, 2024 1,074 $10,000 11,541 (+9.3%) Exercise/Conversion
    EVP Pres., Mfg. Operations
    Officer
    Nov 1, 2024 750 $614,198 30,618 (-2.4%) Payment of Exercise Price
    Evp, Hr Diversity
    Officer
    Nov 1, 2024 681 $557,691 8,042 (-8.5%) Payment of Exercise Price
    EVP Pres., Mfg. Operations
    Officer
    Nov 1, 2024 1,687 $10,000 31,369 (+5.4%) Exercise/Conversion
    EVP CFO
    Officer
    Nov 1, 2024 467 $382,440 11,073 (-4.2%) Payment of Exercise Price
    Director
    Oct 21, 2024 13 $11,780 54,267 (+0.0%) Grant
    Director
    Oct 21, 2024 11 $9,967 1,548 (+0.7%) Grant
    Director
    Oct 21, 2024 16 $14,498 15,825 (+0.1%) Grant
    Director
    Oct 21, 2024 11 $9,967 2,201 (+0.5%) Grant
    Director
    Oct 21, 2024 11 $9,967 2,699 (+0.4%) Grant